Structural Biology in Drug Discovery

Structure-based drug discovery is now a full part of the pharmaceutical industry, and many companies use both high-throughput screening and fragment screening to find starting points for their small-molecule R&D programs.

Knowledge of the 3D structures of proteins has long been acknowledged as having the potential to expedite drug discovery, but recent advancements in genome sequencing, robotics, and bioinformatics have drastically altered the opportunities. Through genomic analyses and X-ray or NMR spectroscopy, numerous new protein targets have been found and examined. Structural biology has been essential in guiding not only lead optimization and target identification, where it has well-established responsibilities, but also lead discovery, now that high-throughput methods of structure determination may provide effective screening approaches.

Tags
cryo-EM Conferences Computational Structural Biology Conferences 2024 Proteomics Conferences 2024 Structural Bioinformatics Conferences Structural Genomics Conferences Structural Biology Conferences Structural Biology Conferences 2024 Europe Genomics Conferences Bioinformatics Conferences Stereochemistry Conferences Protein Engineering Conferences Structural Biology Conferences 2024 cryo-EM Conferences 2024 Bioinformatics Conferences 2024 NMR Spectroscopy Conferences

+1 (506) 909-0537